Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in class innovative cancer therapies

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.

Explicyte has generated proprietary RNA-sequencing-based data from preclinical syngeneic tumor models, enabling it to interrogate and decipher transcriptomics from the tumor and its microenvironment, and to correlate data to the response to prototypical immune checkpoint inhibitors. Data analysis allowed for differential gene expression profiling between animals that respond, or not, to immune checkpoint blockade. Domain Therapeutics has secured exclusive access to Explicyte’s GPCR-related data.

For Domain Therapeutics, these results, cross-validated with clinical RNA-sequencing data, constitute a valuable source of GPCR targets for the development of first-in-class innovative immunotherapies associated with biomarkers; to support the development of personalized medicines in immunotherapy. The GPCR-focused company will enrich its proprietary pipeline of programs with brand new GPCR targets aimed at rearming the immune system and potentiating immune checkpoint inhibitor activity.

Related posts

Domain Therapeutics
admin

Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology

Strasbourg, France – Montreal, Canada, June 28, 2022 – Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Read More »
Domain Therapeutics
admin

Domain Therapeutics raises $42m Series A financing

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

Read More »
Domain Therapeutics
admin

Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration agreement with Domain Therapeutics S.A. (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM”), to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease area

Read More »
Domain Therapeutics
admin

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10m in the fifth call for hospital-university research in health (RHU) projects

January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).

Read More »